Cocrystal Pharma (COCP) Other financing activities (2011 - 2020)

Cocrystal Pharma (COCP) reported Other financing activities of -$11000.0 for Q3 2020, down 375.0% sequentially from $4000.0 in Q2 2020.

Cocrystal Pharma (COCP) Other financing activities (2011 - 2020) Analysis & Trends

Cocrystal Pharma (COCP) has 6 years of Other financing activities data on file, last reported at -$11000.0 in Q3 2020.

For the quarter ending Q3 2020, Other financing activities changed N/A year-over-year to -$11000.0; the trailing twelve-month figure through Sep 2020 stood at $4000.0 (up 102.07% YoY), and the FY2019 full-year result was -$10000.0, down 11.11% from the prior year.
Other financing activities fell to -$11000.0 in Q3 2020, from $4000.0 in the prior quarter.
In the past five years, Other financing activities ranged from a high of $184000.0 in Q1 2018 to a low of -$194000.0 in Q4 2018.
A 3-year average of -$285.71 and a median of $3000.0 in 2016 frame the typical range for Other financing activities.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	Cocrystal Pharma	12.57 Mn	7.74 Mn	-

Download Data